An implant for sleep apnea is one of the few CPAP alternatives. This article compares hypoglossal nerve stimulation and ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Terence Flynn, Morgan Stanley, inquired about Zepbound payer dynamics and access. Patrik Jonsson explained that Medicare coverage related to obstructive sleep apnea (OSA) is anticipated in the second ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

The potential for lifesaving benefits would justify expanding access, said Elizabeth Benge, MD, an instructor in the Division of Sleep Medicine ... or weight loss. Medicare doesn’t cover ...

Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its ...

Related FDA approves weight-loss drug Zepbound to treat sleep apnea FDA says shortage of GLP-1 drug tirzepatide is over Merck reaches weight-loss drug deal worth up to $2 billion with China-based ...

A new analysis published in Otolaryngology–Head and Neck Surgery reveals that for people with sleep apnea, getting surgery for their condition may lessen their risk of such accidents compared ...

Before starting Zepbound a year ago, Klapper struggled with joint pain, sleep apnea, and other health issues. The mother of two young boys found it challenging to engage in play and activities ...